It was found that the expression of NPM2 was significantly different in multiple tumors: in digestive tract tumors such as cholangiocarcinoma (CHOL) and colon adenocarcinoma (COAD) and in non-digestive tract tumors such as adrenocortical carcinoma (ACC), glioblastoma multiforme (GBM), kidney renal clear cell carcinoma (KIRC), acute myeloid leukemia (LAML), brain low-grade glioma (LGG), testicular germ cell tumors (TGCT), and thymoma (THYM) (Fig. 5). This evidence concerns the gene NPM2 and colon adenocarcinoma.